(MedPage Today) — The FDA on Friday granted accelerated approval to zongertinib (Hernexeos) for non-squamous non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain (TKD) activating mutations.
Approval of the tyrosine…
Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/116921
Author :
Publish date : 2025-08-08 21:19:00
Copyright for syndicated content belongs to the linked Source.
